Hematology News

Peter Hillmen, MD, PhD, and John Atkinson, MD, will receive the Ernest Beutler Lecture and Prize at this year’s ASH Annual Meeting & Exposition.

The FDA approved etranacogene dezaparvovec-drlb, a single-dose gene therapy for treatment of adults with hemophilia B.

CHICAGO — In hospitalized medically ill patients, an electronic health record-based decision support system reduced major thromboembolic events compared with usual care, researchers reported.

CHICAGO — Routine antithrombotic use on top of usual care did not improve outcomes in high-risk, medically ill outpatients with SARS-CoV-2 infection vs. placebo, a speaker reported.

CHICAGO — In patients with thrombotic antiphospholipid syndrome, vitamin K antagonists were linked to lower odds of arterial thrombotic events compared with direct oral anticoagulants, according to a meta-analysis.

The FDA granted accelerated approval to cobimetinib for treatment of certain patients of histiocytic neoplasms.

Compared with other direct oral anticoagulants, apixaban was associated with lower rates of gastrointestinal bleeding but similar rates of ischemic stroke and all-cause mortality among adults with atrial fibrillation, data show.

Four individuals have been elected to American Society of Hematology’s executive committee.

Individuals who acquired COVID-19 infection not requiring hospitalization had greatly increased risk for incident venous thromboembolism, according to results of an English population-based cohort study.

The FDA accepted a biologics license application resubmission for valoctocogene roxaparvovec as treatment for adults with severe hemophilia A, according to a press release from the agent’s manufacturer.